Share Name Share Symbol Market Type Share ISIN Share Description
Arix Bioscience Plc LSE:ARIX London Ordinary Share GB00BD045071 ORD 0.001P
  Price Change % Change Share Price Shares Traded Last Trade
  0.50 0.46% 109.50 26,608 10:20:02
Bid Price Offer Price High Price Low Price Open Price
109.00 110.00 109.50 109.00 109.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.34 -61.08 -48.00 141
Last Trade Time Trade Type Trade Size Trade Price Currency
10:29:49 O 10,000 109.01 GBX

Arix Bioscience (ARIX) Latest News

More Arix Bioscience News
Arix Bioscience Investors    Arix Bioscience Takeover Rumours

Arix Bioscience (ARIX) Discussions and Chat

Arix Bioscience Forums and Chat

Date Time Title Posts
27/6/202211:04Arix Bioscience plc458
30/7/201811:14Arix Bioscience (ARIX) One to Watch -

Add a New Thread

Arix Bioscience (ARIX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
09:29:50109.0110,00010,901.00O
09:29:05109.0110,00010,901.00O
09:20:31109.304,0004,372.00O
08:07:51109.402,5002,735.00O
08:03:18109.35108118.10O
View all Arix Bioscience trades in real-time

Arix Bioscience (ARIX) Top Chat Posts

DateSubject
07/7/2022
09:20
Arix Bioscience Daily Update: Arix Bioscience Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker ARIX. The last closing price for Arix Bioscience was 109p.
Arix Bioscience Plc has a 4 week average price of 109p and a 12 week average price of 109p.
The 1 year high share price is 180p while the 1 year low share price is currently 66.68p.
There are currently 129,180,800 shares in issue and the average daily traded volume is 47,093 shares. The market capitalisation of Arix Bioscience Plc is £141,452,976.
09/6/2022
09:25
ohisay: Yes good to see the cash backing spelt out . They should have done the monthly NAV reporting a long time ago ..arguably share price would not be quite as low as it is if they'd done it earlier. Of course Biotech in the US hasnt done at all well since the beginning of last year: though I see a lot of suggestions recently suggesting its bottomed out. I've added a few of these (Arix) as they seem to have changed tack recently in going for semi established companies rather than IPO's. https://seekingalpha.com/symbol/XBI/charting?axis=percentage&compare=XBI,SP500TR,PPH&interval=1Y&metric=priceReturn&series=line
09/6/2022
08:42
spectoacc: I like the clear way ARIX are now presenting the NAV - be good if that was taken up by others, rather than just the "NAV: 177p".
31/5/2022
10:20
spectoacc: Been a decent biotech rally (or dcb more likely). ARIX has singularly failed to partake in it.
30/4/2022
05:38
ohisay: Arix intends to provide regular market updates on its unaudited NAV and is therefore today also releasing its position as of 31 March 2022. The penny has finally dropped !.. 31-Mar-22 Listed GBP53.5m /Unlisted BP57.2m / Cash etc GBP130.6m /Total GBP241.3m /1.87p per share. So cash etc of 101p per share. So at 114p per share current price ..the listed/unlisteds are effectively discounted by 85% if my maths is right . And cash is 89% of the share price .
16/12/2021
15:16
rcturner2: I also think they are mispriced as when you strip the cash out the discount to the actual holdings is absurd. Of course as others have said that doesn't mean the share price will go up. Equally they have to use the cash wisely. The share price being where it is probably reflects market sentiment about how the IT has been run in the recent past.
16/12/2021
15:13
skyship: From P. No. 363 above. Simon Thompson re-tipped these on 8th Nov'21 when they were 140p: ........................... Aura IPO highlights hidden value in Arix’s unquoted portfolio Arix’s holding in Aura Biosciences soars on Nasdaq IPO. The Nasdaq IPO of Aura Biosciences (US:AURA) raised $75.6m at $14 a share and has been well received. The stock is now trading at $18.69 to value the company at $531m. This is important for UK venture capital group Arix Bioscience (ARIX:140p), the laggard in my market-beating 2021 Bargain Shares Portfolio, which holds 1.52m shares in Aura. The stake is now worth $28.4m (£21m), a 75 per cent premium to the valuation in Arix's half-year accounts, and accounts for 30 per cent of the group's listed portfolio of mainly Nasdaq biotech stocks. This means that Arix’s £181m market capitalisation is 15 per cent less than the combined value of its £139m (108p) cash pile and the £73m (56.5p) listed portfolio. You are also getting a free ride on the group’s £53m (41p) unlisted portfolio even though it includes a conservatively valued £25.3m stake in Artios, a developer of precision medicines for the treatment of cancer that raised $153m from investors in a Series C financing round in July 2021. Artios could receive discovery, development, regulatory and sales-based milestones of up to $1.3bn under a collaboration agreement (April 2021) with Novartis, and $860m of milestones per target from last Decemberâ€T82;s agreement with Merck. It’s more likely, though, that one of the pharma giants will bid for the company if its development programmes are successful. Arix shares are being harshly rated, trading almost a third below spot NAV. Buy.
08/11/2021
21:25
boystown: Re-tipped by Simon Thompson FWIW... Aura IPO highlights hidden value in Arix’s unquoted portfolio Arix’s holding in Aura Biosciences soars on Nasdaq IPO. The Nasdaq IPO of Aura Biosciences (US:AURA) raised $75.6m at $14 a share and has been well received. The stock is now trading at $18.69 to value the company at $531m. This is important for UK venture capital group Arix Bioscience (ARIX:140p), the laggard in my market-beating 2021 Bargain Shares Portfolio, which holds 1.52m shares in Aura. The stake is now worth $28.4m (£21m), a 75 per cent premium to the valuation in Arix's half-year accounts, and accounts for 30 per cent of the group's listed portfolio of mainly Nasdaq biotech stocks. This means that Arix’s £181m market capitalisation is 15 per cent less than the combined value of its £139m (108p) cash pile and the £73m (56.5p) listed portfolio. You are also getting a free ride on the group’s £53m (41p) unlisted portfolio even though it includes a conservatively valued £25.3m stake in Artios, a developer of precision medicines for the treatment of cancer that raised $153m from investors in a Series C financing round in July 2021. Artios could receive discovery, development, regulatory and sales-based milestones of up to $1.3bn under a collaboration agreement (April 2021) with Novartis, and $860m of milestones per target from last December’s agreement with Merck. It’s more likely, though, that one of the pharma giants will bid for the company if its development programmes are successful. Arix shares are being harshly rated, trading almost a third below spot NAV. Buy.
08/10/2021
12:34
speedsgh: New ST/IC update released today... Bargain shares: A heavily oversold biotech value recovery play - HTTPS://www.investorschronicle.co.uk/ideas/2021/10/08/bargain-shares-a-heavily-oversold-biotech-value-recovery-play/ ... So, although Arix’s pro-forma net asset value per share has dropped from 214p to 203.5p since 30 June 2021 and the share price is below my 168p advised buy-in price in this year's portfolio, I feel that the investment case is sound. Furthermore, with the shares massively oversold – the 14-day RSI is 18.07, a level not seen since the March 2020 stock market crash – any upbeat newsflow from investee companies could have an accentuated positive impact on the depressed share price. A succssful IPO for Pyxis would be a good start. Buy.
14/8/2021
00:10
daemonfunds: @weatherman Arix Bioscience (ARIX:165p) is the laggard in my 2021 Bargain Shares Portfolio after the share price pulled back below my 168p advised buy in price following interim results from the venture capital company. Arix holds a diversified portfolio of unlisted and listed investments in early stage biotechnology businesses targeting cutting edge advances in life sciences. Share price weakness in four of its Nasdaq quoted investee companies, the decision to close-down another company after reviewing initial pre-clinical work, and adverse foreign currency movements accounted for £28m, £7.5m and £2.5m valuation reversals, respectively, in the first half of 2021. The negative impact was partly offset by £5.5m net gains on other investee companies, but closing net asset value (NAV) of £281m (214p a share) was still well shy of Peel Hunt’s forecast range (£300m to £310m). Post the half year-end, Arix’s listed portfolio has suffered further paper losses of £12.7m and currently has a value of £47.3m (36p a share) after factoring in the follow-on US$8m (£5.8m) investment in Nasdaq-quoted drug development company Imara (NSQ: IMRA). Later this year, Imara is expected to announce interim results from its ongoing Phase 2b clinical studies for IMR-687 in sickle cell disease and beta-thalassemia. Arix has also spent a further £1m on share buy-backs in the second half, and invested £6.3m in portfolio company Artios Pharma’s recent oversubscribed US$153m (£110m) Series C financing round. Artios is a leading DNA Damage Response (DDR) company that is developing a pipeline of precision medicines for the treatment of cancer. In April, Artios entered a research collaboration with drug giant Novartis to discover and validate next-generation DDR targets to enhance Novartis' Radioligand Therapies. I have great hopes for Artios (‘Five investment company bargains’ 8 April 2021) and note some smart investors are backing the company’s management who previously played key roles in AstraZeneca’s discovery of Lynparza, a treatment for advanced ovarian cancer. Factoring in investments made in the second half, Arix’s proforma net cash of £150.7m (115p a share) and its £47.3m (36p a share) listed portfolio back up 92 per cent of the company’s market capitalisation of £215m. This means that Arix’s unlisted portfolio is in the price for £17m, or 75 per cent below its carrying value of £67.5m (51.6p a share), even though the Artios stake is in Arix's books at £25.3m (19.4p a share) and analysts at Jefferies value it at more than double that sum. Importantly, Arix’s new management team has been boosted by the return of Mark Chin as managing director following a shareholder led boardroom clear out. Chin was Arix’s investment director from 2016 to 2020 during which time he sourced and led deals in key portfolio companies, including: VelosBio (acquired by Merck for $2.75bn), and Amplyx Pharmaceuticals (acquired by Pfizer). The team highlights no fewer than eight anticipated milestones across Arix’s portfolio in the second half of this year including: Harpoon Therapeutics (NSQ: HARP) is expected to report interim data from ongoing Phase 1/2 clinical trials in ovarian and pancreatic cancer, multiple myeloma and small cell lung cancer. Artios is set to initiate a Phase 1 clinical study for its Pol-theta inhibitor for the treatment of PARP resistant cancers. LogicBio (NMQ: LOGC) expects to report interim data from its Phase 1/2 clinical study for the treatment of methylmalonic acidemia in paediatric patients. Potential for further valuation upside from unlisted holdings and likely positive newsflow from well-funded listed holdings is not only being materially under-rated, but expect Chin to recycle the cash pile wisely while Arix’s ongoing £25m NAV accretive share buy-back programme – £8m shares were repurchased in the first half – is also supportive. Buy. hTTps://www.investorschronicle.co.uk/ideas/2021/08/12/bargain-shares-a-ben-graham-value-play/
20/2/2020
07:52
stevenb3: Iterium and LogicBio were both up 11% yesterday on NASDAQ. However, I don't expect this to follow through into the Arix share price.
Arix Bioscience share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
ARIX
Arix Biosc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220707 11:21:37